Cargando…
Targeted therapies for gastric cancer: failures and hopes from clinical trials
Gastric cancer is the third leading cause of cancer mortality worldwide. As surgery is the only curative treatment strategy and conventional chemotherapy has shown limited efficacy -with a median overall survival of 10 months- new treatments are urgently needed. Trastuzumab and Ramucirumab (targetin...
Autores principales: | Apicella, Maria, Corso, Simona, Giordano, Silvia |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Impact Journals LLC
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5593674/ https://www.ncbi.nlm.nih.gov/pubmed/28915702 http://dx.doi.org/10.18632/oncotarget.14825 |
Ejemplares similares
-
Molecularly Targeted Therapies for Gastric Cancer. State of the Art
por: Reddavid, Rossella, et al.
Publicado: (2021) -
The importance of being CAFs (in cancer resistance to targeted therapies)
por: Rizzolio, Sabrina, et al.
Publicado: (2022) -
Safety and efficacy of toripalimab in advanced gastric cancer: A new clinical trial bringing hope for immunotherapy in gastric cancer
por: Qiu, Haibo
Publicado: (2020) -
Autocrine Signaling of NRP1 Ligand Galectin-1 Elicits Resistance to BRAF-Targeted Therapy in Melanoma Cells
por: Rizzolio, Sabrina, et al.
Publicado: (2020) -
From the Catastrophic Objective Irreproducibility of Cancer Research and Unavoidable Failures of Molecular Targeted Therapies to the Sparkling Hope of Supramolecular Targeted Strategies
por: Alekseenko, Irina, et al.
Publicado: (2023)